The results of another disease-modifying trial.No doubt the...

The results of another disease-modifying trial.

No doubt the results are "statistically significant....."

Happy Easter to all....

Alois.


"The abstracts for the American Academy of Neurology annual meeting on 10-17 April have been posted on the conference website including Baxsters 18-month, Phase 2 study of IVIG in mild-moderate AD. The 24 patient study demonstrated
that at 18 months, significant differences favouring IVIG treatment were seen on primary and secondary outcome measures. The study concludes that IVIG treatment results in less decline and improvement in areas of neuropsychological functioning, such as basic auditory attention, language and executive function, over 18 months."

Further info on the trial via the link below:

http://clinicaltrials.gov/ct2/show/NCT00299988

"The overall goal of this double-blind Phase II study is to evaluate the safety, efficacy and biological mechanisms of action of Intravenous Immunoglobulin (IVIg) in the treatment of mild to moderate stage Alzheimer's disease (AD). IVIg contains antibodies against the amyloid beta protein that is the central component of the AD senile plaque. It is hypothesized that IVIg treatment will reduce the levels of beta amyloid in the brain and improve cognitive abilities relative to placebo. A total of 24 patients with mild to moderate AD capable of giving informed consent will be randomly assigned to receive either IVIg (16 patients)or saline placebo (8 patients) for six months. This study includes comparison of four dosing regimens of IVIg. Cognitive, behavioral and functional measures will be collected at baseline, three months and six months of treatment and after a six-week washout period. Plasma samples will be collected before and after infusions. Subjects will undergo a lumbar puncture before and after the six months of treatment for cerebrospinal fluid (CSF) biomarker analyses. In addition, Positron Emission Tomography (PET) imaging substudies will be performed at two time points during the study. Following the initial 6 month placebo-controlled period, all participants have the opportunity to receive IVIg for an additional 6 month period."